|
Trigeminal Neuralgia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TN tumors had a higher metabolic activity than HER2 and luminal tumors but no significant differences in global BF values were noted.
|
31396665 |
2020 |
|
Trigeminal Neuralgia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The 5-year regional nodal recurrence (RNR), 5-year distant metastasis-free survival (DMFS) and 5-year disease free-survival (DFS) of TN patients were significantly superior to HER2-overexpression patients (P < .00001).
|
30732191 |
2019 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
On multivariable analysis absence of spiculation and core grade remained significant for the whole cohort, size and absence of spiculation remained significant for HER-2 positive tumours.No feature predicted pCR in TN tumours.
|
31639053 |
2019 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In view of the high ypN0 rate in cN0 patients, axillary surgical staging might be selectively eliminated, especially for HER2+ and TN patients.
|
31332886 |
2019 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
An AUC of 0.763 (95% CI 0.608, 0.917) with a sensitivity of 86.4% and a specificity of 72.2% was achieved for differentiating TN cancers from human epidermal growth factor receptor 2 (HER2) positive cancers.
|
30402704 |
2019 |
|
Trigeminal Neuralgia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CART model identified four risk layers: group 1 (SUVmax ≤6.75 and tumor size ≤2.0 cm); group 2 (SUVmax ≤6.75 and Luminal A [LumA] or TN tumor >2.0 cm); group 3 (SUVmax ≤6.75 and Luminal B [LumB] or human epidermal growth factor receptor 2 [HER2]-enriched] tumor >2.0 cm); group 4 (SUVmax >6.75).
|
29479851 |
2018 |
|
Trigeminal Neuralgia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A better understanding of the expression of cancer/testis antigens (CTAs) in breast cancer might enable the identification of new immunotherapy options, especially for triple-negative (TN) tumours, which lack expression of the conventional therapeutic targets oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
|
29465777 |
2018 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although mutated in 30-35% of all cases, p53 is mutated in approximately 80% of triple-negative (TN) tumors (i.e., tumors negative for ER, PR, and HER2).
|
29564741 |
2018 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the 500 patients with PS TN cancers, MS identified 24 (5%) patients as Luminal-type with 5-year DMFS estimated at 100% versus 71.4% for MS HER-2+ or 90.1% for MS Basal-type.
|
28929359 |
2018 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed at least 1% of PD-L1-positive (PD-L1+) cells in 53.1% of ER+HER2-, 73.3% of HER2+, and 84.4% of TN tumors.
|
30524905 |
2018 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
OS was found to differ significantly between breast cancer subtypes: OS was significantly shorter in patients with triple-negative (TN) cancer compared with patients with human epidermal growth factor receptor (HER2)-enriched tumors (P<0.001).
|
28693153 |
2017 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The metabolic response in breast and axilla correlated moderately in TN tumours (r = 0.57) using ∆SUVmax between PET1-PET3 and poorly in HER2-positive tumours (r = 0.49) using SUVmax at PET2.
|
28545563 |
2017 |
|
Trigeminal Neuralgia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Women with TN tumour subtype had significantly less lymph node invasion when compared to HR+/HER2- subtype (OR = 0.71; CI95% = [0.54-0.92]).
|
28199325 |
2017 |
|
Trigeminal Neuralgia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PIM1 expression was higher in TN tumors than in RP tumors and was associated with poor prognosis in patients with hormone- and HER2-negative tumors.
|
27775705 |
2016 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We classified 30 breast carcinoma samples into three subgroups: 10 luminal-A tumors (ER+/PR+/Her2-), 10 Her-2 tumors (ER-/PR-/Her2+), and 10 triple negative (TN) tumors (ER-/PR-/Her2-).
|
26055977 |
2015 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with unselected breast cancer patients at the same institution, patients with breast cancer who had brain metastases had a higher proportion of hormone receptor-negative, HER2-positive, and TN tumors.
|
25802405 |
2015 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A more limited prognostic impact, not reaching statistical significance, was observed in patients with HER2-positive disease as opposed to patients with Luminal A, Luminal B-HER2-negative and TN disease.
|
24366294 |
2014 |
|
Trigeminal Neuralgia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear VGLL1 expression was observed in 13% of sporadic breast carcinomas, and while VGLL1 was only occasionally found in luminal A (0.70%) and B (5.60%) carcinomas, it was often expressed in HER2-positive (17%), triple-negative (TN) breast carcinomas (>40%) and BRCA1-associated TN carcinomas (>50%).
|
24891455 |
2014 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 5-year RFS rates were 98.2%, 97.1%, and 83.5% in patients with HR(+), HER2(+), and TN tumors, respectively (P < .001).
|
24703318 |
2014 |
|
Trigeminal Neuralgia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BL cancers can be considered a sub-group of Triple negative (TN) cancers since they lack estrogen (ER), progesterone (PR) and Her2 expression.
|
24693876 |
2014 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four of 92 (4 %) IHC/FISH triple-negative (TN) patients were reclassified as Luminal (n = 2) or HER2 (n = 2).
|
25099655 |
2014 |
|
Trigeminal Neuralgia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, most TN tumors identified as HER2E showed low HER2 expression and lacked HER2 amplification, despite the similar overall gene expression profiles to HER2E tumors that were clinically HER2-positive.
|
23404817 |
2013 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA1 promoter hypermethylation (15.4% of all cancers) was significantly associated with uPA and PAI-1 levels, tumour grade, mitotic count score, hormone receptor and HER2 negative status and TN profile (29% of TN tumours showed BRCA1 promoter hypermethylation compared to 5% of grade II-III hormone receptor-positive/HER2-negative and 2% of HER2-positive tumours).
|
24191908 |
2013 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A distinct group of breast cancers, called "basal" or "triple-negative" (TN) cancers express both basal cytokeratins and the epidermal growth factor receptor, but fail to express estrogen receptors, progesterone receptors or HER2 and have stem-like or mesenchymal features.
|
22189713 |
2012 |
|
Trigeminal Neuralgia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD24 cytoplasmic expression was significantly associated with poor prognostic variables including high tumour grade, ER-, PR-, HER2(+), p53+ and triple negative (TN) phenotype; P < 0.05.
|
22119938 |
2012 |